Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-399 in c-Met Positive Squamous Cell Lung Cancer
NCT03574753Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab vedotin in squamous cell carcinoma of the lung (SCCL), sponsored by SWOG Cancer Research Network. Started Mar 2018; status: completed.
02
Drugs
telisotuzumab vedotin
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03574753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574753.